glp-1 companion app companies AI accelerates digital health development with Phlo's GLP1 app | Marc Sluijs posted on the topic Jurni GLP | GLP-1 Companion

Deep Vein Thrombosis (DVT) and Blood Clot Risks A groundbreaking 2021 study published in the Endocrine Journal revealed that Ozempic users face a staggering 266% increased risk of developing deep vein thrombosis compared to patients on other diabetes medications, yet no warnings about blood clot risks appear on the drugs label

MarketScan data shows that only 66% of continuously enrolled new GLP-1 patients were persistent on Obesity medications for at least 40 weeks (10 months) in 2022 2024, compared to 77% of patients taking Diabetes products

Twenty-four studies included individuals with T2D

Semaglutide has randomized trial evidence in nonalcoholic steatohepatitis demonstrating improvement in key disease activity outcomes. Tirzepatide also has randomized trial evidence in metabolic dysfunctionassociated steatohepatitis (MASH) with liver fibrosis, supporting improvements in steatohepatitis-related endpoints. Clinical takeaway: GLP-1 and GLP-1/GIP therapies can reduce liver fat and liver injury activity in metabolic liver disease settings., 3) They Improve Cardiometabolic Risk Factors That Overlap With Vascular Inflammation Vascular inflammation is an umbrella term

Somewhat paradoxically, a final nonsurgical treatment that we believe should be considered in some patients is targeted lipolysis, for example using deoxycholic acid or cryolipolysis

Ozempic Blindness Lawsuit Overview Ozempic blindness lawsuits claim that the drugs manufacturer, Novo Nordisk, failed to adequately warn consumers about the risk of vision loss caused by non-arteritic anterior ischemic optic neuropathy (NAION)